EUVIMEDEUVIMED entdecken
Open Access

NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis

Nicola Potere iD, Evan Garrad, Yogendra Kanthi, Marcello Di Nisio, Gilles Kaplanski, Aldo Bonaventura, Jean Marie Connors, Raffaele De Caterina iD, Antonio Abbate iD

Cardiovascular Research · 05.09.2023 · 119 (11) · 2046-2060

DOI: 10.1093/cvr/cvad084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 30.05.2023. Verfasst von Nicola Potere und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Ageing Sciences, 'G. d'Annunzio' University, Via Luigi Polacchi 11, Chieti 66100, Italy. Hauptthemen laut MEDLINE: Inflammasomes, COVID-19. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunothrombosis—immune-mediated activation of coagulation—is protective against pathogens, but excessive immunothrombosis can result in pathological thrombosis and multiorgan damage, as in severe coronavirus disease 2019 (COVID-19). The NACHT-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome produces major proinflammatory cytokines of the interleukin (IL)-1 family, IL-1β and IL-18, and induces pyroptotic cell death. Activation of the NLRP3 inflammasome pathway also promotes immunothrombotic programs including release of neutrophil extracellular traps and tissue factor by leukocytes, and prothrombotic responses by platelets and the vascular endothelium. NLRP3 inflammasome activation occurs in patients with COVID-19 pneumonia. In preclinical models, NLRP3 inflammasome pathway blockade restrains COVID-19-like hyperinflammation and pathology. Anakinra, recombinant human IL-1 receptor antagonist, showed safety and efficacy and is approved for the treatment of hypoxaemic COVID-19 patients with early signs of hyperinflammation. The non-selective NLRP3 inhibitor colchicine reduced hospitalization and death in a subgroup of COVID-19 outpatients but is not approved for the treatment of COVID-19. Additional COVID-19 trials testing NLRP3 inflammasome pathway blockers are inconclusive or ongoing. We herein outline the contribution of immunothrombosis to COVID-19-associated coagulopathy, and review preclinical and clinical evidence suggesting an engagement of the NLRP3 inflammasome pathway in the immunothrombotic pathogenesis of COVID-19. We also summarize current efforts to target the NLRP3 inflammasome pathway in COVID-19, and discuss challenges, unmet gaps, and the therapeutic potential that inflammasome-targeted strategies may provide for inflammation-driven thrombotic disorders including COVID-19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammasomesCOVID-19HumansNLR Family, Pyrin Domain-Containing 3 ProteinThromboinflammationInterleukin-1betaInflammation

Stichwörter der Autor:innen

COVID-19CoagulationEndotheliopathyInterleukin-1NLRP3 inflammasomePyroptosisThrombosis

Substanzen

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinInterleukin-1beta

Autor:innen und Institutionen

  • Department of Medicine and Ageing Sciences, 'G. d'Annunzio' University, Via Luigi Polacchi 11, Chieti 66100, Italy.
  • Laboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • University of Missouri School of Medicine, Columbia, MO, USA.
  • Aix-Marseille Université, INSERM, INRAE, Marseille, France.
  • Division of Internal Medicine and Clinical Immunology, Assistance Publique - Hôpitaux de Marseille, Hôpital Conception, Aix-Marseille Université, Marseille, France.
  • Department of Internal Medicine, Medicina Generale 1, Medical Center, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, Varese, Italy.

ORCID-Profile: Nicola Potere, Raffaele De Caterina, Antonio Abbate

Förderung

  • NIH

Zitieren

APA

Potere, N., Garrad, E., Kanthi, Y., Di Nisio, M., Kaplanski, G., Bonaventura, A., Connors, J. M., De Caterina, R., & Abbate, A. (2023). NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. Cardiovascular Research, 119(11), 2046-2060. https://doi.org/10.1093/cvr/cvad084

Vancouver

Potere N, Garrad E, Kanthi Y, Di Nisio M, Kaplanski G, Bonaventura A, et al. NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis. Cardiovascular Research. 2023;119(11):2046-2060. doi:10.1093/cvr/cvad084

BibTeX
@article{Potere2023,
  author = {Potere, Nicola and Garrad, Evan and Kanthi, Yogendra and Di Nisio, Marcello and Kaplanski, Gilles and Bonaventura, Aldo and Connors, Jean Marie and De Caterina, Raffaele and Abbate, Antonio},
  title = {NLRP3 inflammasome and interleukin-1 contributions to COVID-19-associated coagulopathy and immunothrombosis},
  journal = {Cardiovascular Research},
  year = {2023},
  volume = {119},
  number = {11},
  pages = {2046--2060},
  doi = {10.1093/cvr/cvad084}
}
Kostenlos starten →